C
Chronix Biomedical
Molecular diagnostics company developing blood tests for monitoring minimal residual disease in cancer patients
About Chronix Biomedical
Chronix Biomedical, Inc. is a molecular diagnostics company that focuses on developing laboratory-developed blood tests designed for therapy monitoring, particularly for patients undergoing chemotherapy. The company operates in the healthcare and biotechnology market, serving primarily oncology patients and healthcare providers. Chronix Biomedical's business model revolves around creating proprietary diagnostic tests that can predict the effectiveness of cancer treatments and monitor disease progression. Revenue is generated through licensing agreements, such as the one with Amedes Group, and by providing diagnostic services to healthcare institutions. The company leverages advanced molecular techniques to offer precise and timely diagnostic information, which is crucial for personalized cancer treatment plans.
Source: Dealroom company dataAt a glance
- Founded
- 1997
- Headquarters
- San Jose, United States
- Sector
- Biotech & Life Sciences
Latest news
Press, funding announcements and product moves mentioning Chronix Biomedical.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Boston Harbor Angels
Valhalla Private Capital
Series A2 investors entered at this stage
- PPPrairieGold Venture Partners
Pentagram
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Chronix Biomedical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Chronix Biomedical on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.